BioMedNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Announces Acquisition of BlueSky Wellness, Expands Footprint in Global Wellness Market

Lucy Scientific Discovery (NASDAQ: LSDI), a publicly traded company focused on the development, sale, delivery and manufacturing of psychotropic products, is acquiring BlueSky Wellness Inc. and the BlueSky portfolio of brands. According to the announcement, the acquisition adds psychotropic products to the company’s catalog, enabling LSDI to expand its footprint in the global wellness market. BlueSky Wellness brands include Keoni, Keoni Sport, Blush Wellness and AMMA Healing, which have generated more than $20 million in revenue in each of the last two years; BlueSky products range from full-spectrum oils to edible goods, gummies, topicals and beauty products. As part of the BlueSky acquisition, BlueSky shareholders will receive 3.5 million shares of LSDI stock along with annual earn-out payments based on a multiple of annual EBITDA in each of the next five years. LSDI also recently announced the planned acquisition of all High Times IP and brand assets.

The company noted that once it closes on both the High Times and BlueSky Wellness transactions, it anticipates having an estimated 25 million shares issued and outstanding with the two transactions together projected to add a minimum of $30 million of revenue and $10 million of EBITDA for the first 12-month period after closing. “The addition of the BlueSky portfolio and its team allows us to capitalize on revenue opportunities,” said Lucy Scientific Discovery CEO Richard Nanula in the press release. “Coupled with our High Times acquisition, this strategically positions us for substantial near and long-term growth. This acquisition is a testament to our commitment to expand and grow our business, adding revenue that diversifies our company and should deliver significant value to our Lucy Scientific shareholders.”

To view the full press release, visit https://ibn.fm/XzhiS

About Lucy Scientific Discovery Inc.

Lucy Scientific Discovery is a NASDAQ company with holdings and operations in a variety of psychotropic businesses. The company holds a Controlled Drugs and Substances Dealer’s license granted by Health Canada’s Office of Controlled Substances. Lucy Scientific Discovery Inc. and its wholly owned subsidiary, LSDI Manufacturing Inc., operate under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada). This specialized license authorizes LSDI to develop, sell, deliver and manufacture pharmaceutical-grade active pharmaceutical ingredients (“APIs”) used in controlled substances and their raw material precursors. With a focus on pioneering innovative therapies for patients in need, Lucy Scientific Discovery is dedicated to advancing the understanding and applications of psychotropic medicines, improving mental health outcomes and enhancing well-being for individuals worldwide. For more information, visit the company’s website at www.LucyScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to LSDI are available in the company’s newsroom at https://ibn.fm/LSDI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN